IRMD SEC Filing News — IRADIMED CORPORATION

Latest SEC filings for IRADIMED CORPORATION (IRMD) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-25.

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also p…
Sector: Healthcare Industry: Medical Devices Market Cap: $1.1B CIK: 1325618
20
Total Filings
0
Bullish Classifications
10
Bearish Classifications
12
Insider Transactions
4
Material Events (8-K)
2
Periodic Reports
Rule-based classifications for IRMD currently lean bearish. Of the 20 filing records displayed, 10 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
IRMD Filing Activity Snapshot 2026-04-15 — 2026-09-25
Insider Transactions (Form 4)
0 buys vs 10 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$697.2K
Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) · 2026-04-15
7,500 shares · Form 4
Form 144 Notices
2
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for IRADIMED CORPORATION.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 10 open-market sale and 2 option exercise. 10 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×10
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Option exercise ×2
The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Form 4 Option exercise Tax / Compensation Filing 2026-09-25

IRMD insider Form 4 filed for equity award, exercise, or tax withholding

KIANI JOE E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 698 — —
M Option exercise derivative · Restricted Stock Units 698 — —
Filing: Form 4 (Insider Transaction) Insider: KIANI JOE E (Director) Shares: 698
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-08

IRMD insider ALLEN MONTY K (Director) sold 1,419 shares (~$122.6K)

ALLEN MONTY K, listed as Director at IRADIMED CORP, reported an open-market sale of 1,419 IRMD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,014 $86.44 $87.7K
S Open-market sale 405 $86.35 $35.0K
Filing: Form 4 (Insider Transaction) Insider: ALLEN MONTY K (Director) Shares: 1,419 Est. Value: $122.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-06-23

IRMD insider Form 4 filed for equity award, exercise, or tax withholding

GLENN JOHN (CFO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 5,796 — —
F Tax withholding on vested shares 2,319 $92.20 $213.8K
M Option exercise derivative · Restricted Stock Units 5,796 — —
Filing: Form 4 (Insider Transaction) Insider: GLENN JOHN (CFO) Shares: 8,115
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-04

IRMD insider Scharen-Guivel Hilda Frederique (Director) sold 3,000 shares (~$285.0K)

Scharen-Guivel Hilda Frederique, listed as Director at IRADIMED CORP, reported an open-market sale of 3,000 IRMD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,766 $95.00 $167.8K
S Open-market sale 1,234 $95.00 $117.2K
Filing: Form 4 (Insider Transaction) Insider: Scharen-Guivel Hilda Frederique (Director) Shares: 3,000 Est. Value: $285.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-02

IRMD insider Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) sold 2,500 shares (~$226.5K)

Susi Roger E., listed as Director, CEO, President, Chairman, 10% Owner at IRADIMED CORP, reported an open-market sale of 2,500 IRMD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 400 $88.68 $35.5K
S Open-market sale 775 $89.79 $69.6K
S Open-market sale 401 $91.08 $36.5K
S Open-market sale 924 $91.91 $84.9K
Filing: Form 4 (Insider Transaction) Insider: Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) Shares: 2,500 Est. Value: $226.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-28

IRMD insider Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) sold 7,500 shares (~$691.0K)

Susi Roger E., listed as Director, CEO, President, Chairman, 10% Owner at IRADIMED CORP, reported an open-market sale of 7,500 IRMD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 3,111 $91.81 $285.6K
S Open-market sale 1,889 $92.93 $175.5K
S Open-market sale 2,167 $91.85 $199.0K
S Open-market sale 333 $92.61 $30.8K
Filing: Form 4 (Insider Transaction) Insider: Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) Shares: 7,500 Est. Value: $691.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-20

IRMD insider Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) sold 7,500 shares (~$657.3K)

Susi Roger E., listed as Director, CEO, President, Chairman, 10% Owner at IRADIMED CORP, reported an open-market sale of 7,500 IRMD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 298 $85.95 $25.6K
S Open-market sale 3,451 $87.35 $301.4K
S Open-market sale 1,251 $88.34 $110.5K
S Open-market sale 653 $87.13 $56.9K
S Open-market sale 1,841 $88.14 $162.3K
S Open-market sale 6 $88.65 $531.90
Filing: Form 4 (Insider Transaction) Insider: Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) Shares: 7,500 Est. Value: $657.3K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-13

IRMD insider Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) sold 7,500 shares (~$631.3K)

Susi Roger E., listed as Director, CEO, President, Chairman, 10% Owner at IRADIMED CORP, reported an open-market sale of 7,500 IRMD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,773 $84.08 $149.1K
S Open-market sale 1,001 $84.94 $85.0K
S Open-market sale 315 $85.90 $27.1K
S Open-market sale 3,307 $83.70 $276.8K
S Open-market sale 1,104 $84.59 $93.4K
Filing: Form 4 (Insider Transaction) Insider: Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) Shares: 7,500 Est. Value: $631.3K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-06

IRMD insider Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) sold 7,500 shares (~$642.9K)

Susi Roger E., listed as Director, CEO, President, Chairman, 10% Owner at IRADIMED CORP, reported an open-market sale of 7,500 IRMD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 2,447 $85.32 $208.8K
S Open-market sale 1,103 $86.26 $95.1K
S Open-market sale 200 $87.05 $17.4K
S Open-market sale 600 $83.78 $50.3K
S Open-market sale 1,322 $85.56 $113.1K
S Open-market sale 1,650 $86.43 $142.6K
S Open-market sale 178 $87.31 $15.5K
Filing: Form 4 (Insider Transaction) Insider: Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) Shares: 7,500 Est. Value: $642.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-04-30

IRMD insider Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) sold 7,500 shares (~$657.7K)

Susi Roger E., listed as Director, CEO, President, Chairman, 10% Owner at IRADIMED CORP, reported an open-market sale of 7,500 IRMD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 2,819 $88.98 $250.8K
S Open-market sale 931 $89.70 $83.5K
S Open-market sale 998 $84.13 $84.0K
S Open-market sale 847 $85.77 $72.6K
S Open-market sale 742 $86.52 $64.2K
S Open-market sale 900 $88.00 $79.2K
S Open-market sale 263 $88.81 $23.4K
Filing: Form 4 (Insider Transaction) Insider: Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) Shares: 7,500 Est. Value: $657.7K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-04-22

IRMD insider Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) sold 7,500 shares (~$694.1K)

Susi Roger E., listed as Director, CEO, President, Chairman, 10% Owner at IRADIMED CORP, reported an open-market sale of 7,500 IRMD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 3,580 $93.14 $333.4K
S Open-market sale 1,420 $93.90 $133.3K
S Open-market sale 1,162 $89.73 $104.3K
S Open-market sale 140 $90.60 $12.7K
S Open-market sale 606 $91.65 $55.5K
S Open-market sale 592 $92.66 $54.9K
Filing: Form 4 (Insider Transaction) Insider: Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) Shares: 7,500 Est. Value: $694.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-04-15

IRMD insider Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) sold 7,500 shares (~$697.2K)

Susi Roger E., listed as Director, CEO, President, Chairman, 10% Owner at IRADIMED CORP, reported an open-market sale of 7,500 IRMD shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,847 $91.84 $169.6K
S Open-market sale 2,564 $92.79 $237.9K
S Open-market sale 589 $93.45 $55.0K
S Open-market sale 2,107 $93.71 $197.4K
S Open-market sale 393 $94.55 $37.2K
Filing: Form 4 (Insider Transaction) Insider: Susi Roger E. (Director, CEO, President, Chairman, 10% Owner) Shares: 7,500 Est. Value: $697.2K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 2 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. IRADIMED CORPORATION has 2 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-03

IRMD Form 144 filed for proposed insider sale by Monty K. Allen (1,419 shares) ~$122.6K

Monty K. Allen filed a Form 144 with the SEC indicating intent to sell IRMD (IRADIMED CORP) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Monty K. Allen Shares: 1,419 Est. Value: $122.6K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-04

IRMD Form 144 filed for proposed insider sale by Hilda Scharen-Guivel (3,000 shares) ~$285.0K

Hilda Scharen-Guivel filed a Form 144 with the SEC indicating intent to sell IRMD (IRADIMED CORP) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Hilda Scharen-Guivel Shares: 3,000 Est. Value: $285.0K
View on SEC EDGAR → Open Filing Document →
Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for IRADIMED CORPORATION. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K/A Amended Material Company Update 2026-08-18

IRMD filed amended 8-K — material company event

IRADIMED CORP filed an amended 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K/A (Material Event Amendment)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-31

IRMD filed 8-K — material company event

IRADIMED CORP filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-24

IRMD filed 8-K — material company event

IRADIMED CORP filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-05-01

IRMD filed 8-K — material company event

IRADIMED CORP filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 2 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 2 quarterly reports (10-Q) for IRADIMED CORPORATION.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-31

IRMD filed Quarterly Report (10-Q)

IRADIMED CORP filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →
Form 10-Q Quarterly Report 2026-05-01

IRMD filed Quarterly Report (10-Q)

IRADIMED CORP filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify IRADIMED CORPORATION's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on IRMD. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — IRMD SEC Filings

More Tools for IRMD

IRMD Full Stock Analysis IRMD Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper IRMD analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the IRMD stock analysis page.

IRMD Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer